$8.37
1.52% day before yesterday
Nasdaq, Nov 01, 08:07 pm CET
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Theravance Biopharma Inc Target price 2024 - Analyst rating & recommendation

Theravance Biopharma Inc Classifications & Recommendation:

Buy
40%
Hold
60%

Theravance Biopharma Inc Price Target

Target Price $13.20
Price $8.28
Potential
Number of Estimates 5
5 Analysts have issued a price target Theravance Biopharma Inc 2025 . The average Theravance Biopharma Inc target price is $13.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 2 Analysts recommend Theravance Biopharma Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Theravance Biopharma Inc stock has an average upside potential 2025 of . Most analysts recommend the Theravance Biopharma Inc stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 57.42 60.93
11.82% 6.12%
Net Margin -85.20% -57.37%
75.50% 32.66%

3 Analysts have issued a sales forecast Theravance Biopharma Inc 2024 . The average Theravance Biopharma Inc sales estimate is

$60.9m
Unlock
. This is
1.75% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$64.1m 3.35%
Unlock
, the lowest is
$57.1m 7.93%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $57.4m 11.82%
2024
$60.9m 6.12%
Unlock
2025
$75.6m 24.12%
Unlock
2026
$104m 36.91%
Unlock
2027
$115m 11.02%
Unlock
2028
$171m 48.49%
Unlock

5 Theravance Biopharma Inc Analysts have issued a net profit forecast 2024. The average Theravance Biopharma Inc net profit estimate is

$-35.0m
Unlock
. This is
22.32% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$490k 101.09%
Unlock
, the lowest is
$-55.9m 24.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-48.9m 72.60%
2024
$-35.0m 28.54%
Unlock
2025
$2.2m 106.29%
Unlock
2026
$15.4m 597.73%
Unlock
2027
$-15.2m 199.02%
Unlock
2028
$22.3m 246.91%
Unlock

Net Margin

2023 -85.20% 75.50%
2024
-57.37% 32.66%
Unlock
2025
2.91% 105.07%
Unlock
2026
14.83% 409.62%
Unlock
2027
-13.22% 189.14%
Unlock
2028
13.08% 198.94%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.00 -0.71
72.60% 29.00%
P/E negative
EV/Sales 5.84

5 Analysts have issued a Theravance Biopharma Inc forecast for earnings per share. The average Theravance Biopharma Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.71
Unlock
. This is
22.83% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.01 101.09%
Unlock
, the lowest is
$-1.14 23.91%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.00 72.60%
2024
$-0.71 29.00%
Unlock
2025
$0.05 107.04%
Unlock
2026
$0.31 520.00%
Unlock
2027
$-0.31 200.00%
Unlock
2028
$0.46 248.39%
Unlock

P/E ratio

Current -8.96 271.78%
2024
-11.59 29.35%
Unlock
2025
183.80 1,685.85%
Unlock
2026
26.38 85.65%
Unlock
2027
-26.64 200.99%
Unlock
2028
18.14 168.09%
Unlock

Based on analysts' sales estimates for 2024, the Theravance Biopharma Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.73 18.61%
2024
5.84 1.87%
Unlock
2025
4.70 19.44%
Unlock
2026
3.43 26.96%
Unlock
2027
3.09 9.93%
Unlock
2028
2.08 32.66%
Unlock

P/S ratio

Current 6.53 29.78%
2024
6.65 1.78%
Unlock
2025
5.36 19.44%
Unlock
2026
3.91 26.96%
Unlock
2027
3.52 9.93%
Unlock
2028
2.37 32.66%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today